You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 02/08/2016

Company Name Symbol %Change
GRANA Y MONT GRAM
13.13%
ORASURE TECH OSUR
6.27%
TYSON FOODS TSN
5.36%
CENTERSTATE CSFL
5.26%
LEMAITRE VAS LMAT
4.43%

Tale of the Tape

New Strong Sell Stocks for February 8th

Posted Mon Feb 08, 09:30 am ET

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Alliance Resource Partners, L.P. (ARLP)
  • BlackRock, Inc. (BLK)
  • CAI International Inc (CAI)
  • Carmike Cinemas, Inc. (CKEC)
  • CyrusOne Inc (CONE)
View the entire Zacks Rank #5 List.

 

New Strong Buy Stocks for February 8th

Posted Mon Feb 08, 09:30 am ET

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

  • 1st Constitution Bancorp (FCCY)
  • CenterState Banks Inc (CSFL)
  • Cincinnati Financial Corporation (CINF)
  • Clean Energy Fuels Corp (CLNE)
  • Cooper Tire & Rubber Co (CTB)

View the entire Zacks Rank #1 List.

 

Why Sanofi (SNY) Might Surprise This Earnings Season

Posted Mon Feb 08, 09:00 am ET

by Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and Sanofi SNY may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Sanofi is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for SNY in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 72 cents per share for SNY, compared to a broader Zacks Consensus Estimate of 70 cents per share. This suggests that analysts have very recently bumped up their estimates for SNY, giving the stock a Zacks Earnings ESP of 2.86% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that SNY has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Sanofi, and that a beat might be in the cards for the upcoming report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Should You Sell Panera Bread (PNRA) Before Earnings?

Posted Mon Feb 08, 08:59 am ET

by Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and Panera Bread Company PNRA may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Panera Bread is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for PNRA in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at $1.81 per share for PNRA, compared to a broader Zacks Consensus Estimate of $1.78 per share. This suggests that analysts have very recently bumped up their estimates for PNRA, giving the stock a Zacks Earnings ESP of 1.69% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that PNRA has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Panera Bread, and that a beat might be in the cards for the upcoming report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Earnings Estimates Moving Higher for Facebook (FB): Time to Buy?

Posted Mon Feb 08, 08:59 am ET

by Zacks Equity Research

Facebook, Inc. FB is an Internet Services company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on FB’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Facebook could be a solid choice for investors.

Current Quarter Estimates for FB

In the past 30 days, 5 estimates have gone higher for Facebook while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 39 cents a share 30 days ago, to 44 cents per share today, a move of 12.8%.

Current Year Estimates for FB

Meanwhile, Facebook’s current year figures are also looking quite promising, with 7 estimates moving higher in the past month, compared to 2 lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $2.11 per share 30 days ago to $2.36 per share today, an increase of 11.8%.

Bottom Line

The stock has also started to move higher lately, adding 6.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Why SolarCity (SCTY) Might Surprise This Earnings Season

Posted Mon Feb 08, 08:58 am ET

by Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and SolarCity Corporation SCTY may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Hasbro is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for SCTY in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of $2.54 per share for SCTY, compared to a broader Zacks Consensus Estimate of a loss at $2.57 per share. This suggests that analysts have very recently bumped up their estimates for SCTY, giving the stock a Zacks Earnings ESP of 1.17% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that SCTY has a Zacks Rank #3 (Hold) and an SCTY in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Hasbro, and that a beat might be in the cards for the upcoming report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Why Seres Therapeutics (MCRB) Might Surprise This Earnings Season

Posted Mon Feb 08, 08:58 am ET

by Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and Seres Therapeutics, Inc. MCRB may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Seres Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for MCRB in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 38 cents per share for MCRB, compared to a broader Zacks Consensus Estimate of a loss of 40 cents per share. This suggests that analysts have very recently bumped up their estimates for MCRB, giving the stock a Zacks Earnings ESP of 5.00% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that MCRB has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Seres Therapeutics, and that a beat might be in the cards for the upcoming report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Is a Surprise Coming for Instructure (INST) This Earnings Season?

Posted Mon Feb 08, 08:56 am ET

by Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and Instructure, Inc. INST may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Instructure is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for INST in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 60 cents per share for INST, compared to a broader Zacks Consensus Estimate of a loss of 64 cents per share. This suggests that analysts have very recently bumped up their estimates for INST, giving the stock a Zacks Earnings ESP of 6.25% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that INST has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Instructure, and that a beat might be in the cards for the upcoming report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Can ADTRAN (ADTN) Run Higher on Strong Earnings Estimate Revisions?

Posted Mon Feb 08, 08:55 am ET

by Zacks Equity Research

ADTRAN, Inc. ADTN is a Communications Infrastructure company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ADTN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that ADTRAN could be a solid choice for investors.

Current Quarter Estimates for ADTN

In the past 30 days, 2 estimates have gone higher for ADTRAN compared to 0 lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 4 cents a share 30 days ago, to 8 cents per share today, a move of 100%.

Current Year Estimates for ADTN

Meanwhile,ADTRAN’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to 0 lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 56 cents per share 30 days ago to 64 cents per share today, an increase of 14.3%.

Bottom Line

The stock has also started to move higher lately, adding 9.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Should You Buy Health Net (HNT) Ahead of Earnings?

Posted Mon Feb 08, 08:54 am ET

by Zacks Equity Research

Investors are always looking for stocks that are poised to beat at earnings season and Health Net, Inc. HNT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Health Net is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for HNT in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 67 cents per share for HNT, compared to a broader Zacks Consensus Estimate of 66 cents per share. This suggests that analysts have very recently bumped up their estimates for HNT, giving the stock a Zacks Earnings ESP of 1.52% heading into earnings season.

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that HNT has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Clearly, recent earnings estimate revisions suggest that good things are ahead for Health Net, and that a beat might be in the cards for the upcoming report.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Full Archive

The content contained in this weblog feature may have been abstracted from a complete Zacks Equity Research report.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.